Colorectal Cancer Clinical Trial
Official title:
Health Message Framing to Improve Uptake of Bowel Cancer Screening
The objective of this research is to investigate whether a text message (SMS message)
prompting participation in the UK national bowel cancer screening programme improves uptake
for those who have not responded to the test.
The secondary objective is to investigate whether the framing/phrasing of the text message
improves participation , whether by stating the benefits of uptake or alternatively by
stating the costs of non-uptake.
A national register exists for GP practices to identify which patients of theirs have or have
not participated in a national bowel cancer screening programme. A sample of 1600 patients
belonging to a particular practice in Scotland aged between 50 and 74 have been identified as
having received the test kit but have not responded to it. These individuals have also
previously consented to being contacted by the practice via phone text/SMS message for
reminders.
The sample will be randomised into three equally populated groups:
- One group will act as the control arm and will receive no text message.
- One group will receive a text message which encourages participation in the screening
programme and provides information on the cost of not participating (negative frame) -
"If you do not take part in screening then you increase the risk of having an
undiagnosed tumor."
- One group will receive a text message which encourages participation in the screening
programme and provides information on the benefit of participating (positive frame) -
"If you take part in screening then you decrease the risk of having an undiagnosed
tumor."
Both text messages will include a weblink which will direct individuals receiving the text to
find more information and also with instructions on how to order another kit should they have
misplaced the kit that was mailed out to them.
The observation period will last 6 months and patients receiving the text will receive 3
texts in total. One at the start of the 6 months and another every two months after that.
These messages will not change or alternate, that is the negatively framed group will receive
the same text once every 2 months on 3 occasions in total and vice versa. Other studies have
used shorter intervals between text messages to encourage change, although 6 months to 1 year
is a standard amount of time overall. The researchers feel that while more regular messages
may be more likely prompt behaviour there is also a risk of over-burdening the patient with
reminders, as such 3 texts over 6 months was decided upon as a reasonable frequency.
At the end of the 6 months data on uptake of screening for those 1600 patients during that
time will be extracted by the practice clinician, matched with patient characteristics (e,g,
age, sex) and anonymised so that patients cannot be identified. This will then be sent to the
health economist to analyse the data and test the hypotheses above. Regression analysis will
be used to see whether a differential pattern of uptake exists between groups receiving and
not receiving the text message.
Once analysed the results will be fed back to the practice in order to help inform future
reminders and will also be drafted into a paper to be submitted for peer-review.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
| Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
| Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
| Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
| Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |